Previously, IFNγ was thought to be solely detrimental during MS; however, recent research is shedding light on the protective mechanisms induced by IFNγ signaling during chronic disease, a timepoint where MS therapies are critically lacking. The gene discussed is IFNG; the disease is myeloid sarcoma.